Corporate Address Fannin South Professional Building, Suite 140 Houston, Texas 77054
Exhibit 10.1
Xxxxxxxxx Xxxxxxx
Xxxxxx Xxxxx Xxxxxxxxxxxx
Xxxxxxxx, Xxxxx 000
0000 Xxxxxx Xxxxxx
Xxxxxxx, Xxxxx 00000
t: 832.968.4888
Transition and Consulting Agreement
February 9, 2022
Xxxxxxxx Xxxxxx
Dear Xx. Xxxxxx:
Kiromic BioPharma, Inc., a Delaware corporation (the “Company”), is pleased to offer this Transition and Consulting Agreement (this “Agreement”), effective as of February 9, 2022 (the “Effective Date”), to Xx. Xxxxxxxx Xxxxxx (“Consultant,” together with the Company, the “Parties” and, each, a “Party”) in connection with the termination of his employment with the Company and retention as an independent contractor to perform certain consulting services. In consideration of the mutual promises and agreements contained in this Agreement, and other valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:
844.KEY.CURE | xxx.xxxxxxx.xxx
21797328.8 | | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 2 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 3 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 4 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 5 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 6 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 7 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 8 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 9 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 10 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 11 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 12 | |
Xxxxxxxx Xxxxxx
February 9, 2022
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 13 | |
Xxxxxxxx Xxxxxx
February 9, 2022
If to the Company:
Kiromic BioPharma, Inc.
Attention: CFO
0000 Xxxxxx Xxxxxx, Xxxxx 000
Xxxxxxx, XX, 00000
If to Executive:
At the most recent address on file with the Company
With a courtesy copy to Consultant’s counsel who represented him in connection with the Agreement, Xxxxxx Xxxxxx of Xxxxx Lovells
[The remainder of this page is intentionally blank; signature page follows.]
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 14 | |
Xxxxxxxx Xxxxxx
February 9, 2022
IN WITNESS WHEREOF, the Parties have executed this Agreements as of the Effective Date.
CONSULTANT /s/ Xxxxxxxx Xxxxxx Xxxxxxxx Xxxxxx | KIROMIC BIOPHARMA INC. By:/s/ Xxxxxx Xxxxxxx Name: Pietro Bersani Title: Interim Chief Executive Officer |
[Signature page to Transition and Consulting Agreement.]
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 15 | |
EXHIBIT A
SUPPLEMENTAL GENERAL RELEASE OF CLAIMS
This Waiver and General Release Agreement (“Release”) is executed by Xxxxxxxx Xxxxxx (“Consultant”) on this day of ______________ , ____.
1.Waiver and General Release. Consultant, on behalf of himself and his heirs, executors, administrators, family members, attorneys and assigns, hereby waives, generally releases and forever discharges Kiromic BioPharma, Inc. (the “Company”), together with the Company’s directors, subsidiaries, divisions and affiliates, whether direct or indirect, its and their joint ventures and joint venturers (including each of their respective directors, officers, employees, shareholders, members, managers, partners, attorneys, insurers, and agents, past, present, and future), and each of its and their respective successors and assigns (hereinafter collectively referred to as “Releasees”), from any and all known or unknown actions, causes of action, suits, complaints, contracts (whether oral or written, express or implied from any source), promises and liabilities of any kind, in law or equity, that Consultant ever had, may now have or hereafter can, will or may have against the Releasees as of and including the Release Effective Date (defined below), including, but not limited to:
a. | claims, actions, causes of action or liabilities arising under Title VII of the Civil Rights Act, the Age Discrimination in Employment Act (the “ADEA”), the Older Workers Benefits Protection Act (the “OWBPA”), the Equal Pay Act, the Fair Labor Standards Act, the Employee Retirement Income Security Act, the Rehabilitation Act, the Americans with Disabilities Act, Section 1981 of the Civil Rights Act, the 1991 Civil Rights Act, the Family and Medical Leave Act, and/or any other federal, state, municipal or local employment discrimination statutes or ordinances (including, but not limited to, claims based on age, sex, attainment of benefit plan rights, race, religion, national origin, marital status, sexual orientation, ancestry, harassment, parental status, handicap, disability, retaliation, and veteran status); and/or |
b. | claims, actions, causes of action or liabilities arising under any other federal, state, municipal, or local statute, law, ordinance or regulation; and/or |
c. | future causes of action under the federal false claims act and/or any state false claims act relating in any manner to information learned while employed with the Company; and/or |
844.KEY.CURE | xxx.xxxxxxx.xxx
21797328.8 | | |
d. | any other claim whatsoever including, but not limited to, claims for severance pay, sick pay, unpaid wages, unpaid bonuses, unpaid paid time off, claims based upon breach of contract, breach of the covenant of good faith and fair dealing, wrongful termination, defamation, interference with contract, intentional and/or negligent infliction of emotional distress, fraud, tort, personal injury, invasion of privacy, violation of public policy, negligence and/or any other common law, statutory or other claim whatsoever arising out of or relating to his employment with and/or separation from employment with the Company and/or any of the other Releasees, but excluding any claims that by law Consultant cannot waive, including claims for indemnification, and any claim that the Company has failed to make any payments or to provide any of the payments or benefits described in the Transition and Consulting Agreement, dated as of February 9, 2022, between Consultant and the Company (the “Consulting Agreement”). |
2.Remedies if Consultant Breaches Waiver and Release. Consultant further acknowledges and agrees that if he breaches the provisions of the waiver and release, then to the fullest extent permitted by law, (a) the Company will be entitled to apply for and receive an injunction to restrain any violation of the waiver and release, (b) the Company will not be obligated to make any additional payments or provide any additional benefits, and (c) Consultant will be obligated to pay to the Company its costs and expenses in enforcing the waiver and release and defending against such lawsuit (including court costs, expenses and reasonable legal fees) if Company is the prevailing party.
3.Waiver of Reinstatement Rights. To the extent permitted by law, Consultant further waives, releases, and discharges Releasees from any reinstatement rights that Consultant has or could have.
4.Representations and Warranties of Consultant. Consultant expressly represents and warrants that (a) he is the sole owner of the actual or alleged claims, demands, rights, causes of action, and other matters that are released by Consultant herein; (b) the same have not been transferred or assigned or caused to be transferred or assigned to any other person, firm, corporation or other legal entity; and (c) Consultant has the full right and power to grant, execute and deliver the releases, undertakings, and agreements contained herein. Consultant further represents and warrants that he is unaware of any lien that has been noticed or filed and that would attach to any payment or benefit to be made or given by the Company pursuant to this Release. Consultant agrees to indemnify the Releasees, including payment of any attorneys’ fees and costs, and hold the Releasees harmless from and against any and all damages that may be suffered by them in the event that any of the foregoing representations and warranties are
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 2 | |
untrue in whole or part, and any and all claims based on or arising from any such assignment or transfer, or any attempted assignment or transfer, of any matters released herein.
5.Release of Known and Unknown Claims and Claims Under Age Discrimination in Employment Act. Consultant understands that this waiver and release includes a release of all known and unknown claims, including claims under the federal ADEA. Consultant acknowledges that this Release does not waive any right or claim that he may have under the ADEA, as amended by the OWBPA, that arises after the Release Effective Date.
6.Knowing and Voluntary Waiver. Consultant further acknowledges and agrees that he has carefully read and fully understands all of the provisions of this waiver and release and that he has obtained representation by counsel in connection with his execution of this waiver and release. Consultant has freely, knowingly and voluntarily elected to execute this Release, in exchange for due consideration, by signing below. Consultant further acknowledges that he (i) is not relying upon any statements, understandings, representations, expectations, or agreements other than those expressly set forth in this Release; (ii) has made his own investigation of the facts and is relying solely upon his own knowledge; and (iii) knowingly waives any claim that this Release was induced by any misrepresentation or nondisclosure and any right to rescind or avoid this Release based upon presently existing facts, known or unknown. Consultant acknowledges that the Company has provided him with the disclosure information pursuant to the ADEA and OWBPA (under Title 29 U.S.C. Section 626(f)(1)(H)), attached as Exhibit 1 to this Release.
7.Protected Rights. Consultant understands that nothing contained in this Release prohibits or limits Consultant’s ability to file a charge or complaint with any federal, state or local governmental agency or commission. Consultant also understands that this Release does not prohibit or limit Consultant’s ability to communicate with any federal, state or local governmental agency or commission, or to otherwise participate in any investigation or proceeding that may be conducted by such an agency or commission, including providing documents or other information.
8.Cooperation. In consideration for the payments and agreements set forth in the Consulting Agreement, Consultant agrees, upon request of the Company, to cooperate with the Company and its subsidiaries and affiliates with reasonable advance notice to provide information to and assist the Company, and its subsidiaries and affiliates in the investigation, defense, or prosecution of any suspected claim against or by the Company and its/their subsidiaries and affiliates or any Releasee. Such assistance will include, but is not limited to, participating in interviews with representatives of the Company, attending, as a witness, depositions, trials, or other similar proceedings without requiring a subpoena, and producing and/or providing any documents or names of other persons with relevant information. Consultant further agrees that he will provide full, complete and truthful information and testimony in all interviews, meetings, and/or testimony. Consultant understands that Company
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 3 | |
will reimburse Consultant for reasonable out-of-pocket expenses incurred as a result of such cooperation. Consultant will act in good faith to furnish the information and cooperation required by this Section 8 (Cooperation), and the Company will act in good faith so that the requirement to furnish such information and cooperation does not create a hardship for Consultant.
9.Time to Consider Release; Revocation. Consultant acknowledges that he has had at least 21 calendar days after the receipt of this Release to consider signing this Release and that he may voluntarily choose to waive this 21-day period. In addition, Consultant has seven calendar days after signing the Release to revoke it, in which case this Release will be null and void. Any such revocation must be in writing and be submitted to Kiromic BioPharma, Inc., Attn: CFO, 0000 Xxxxxx Xxxxxx, Xxxxx 000; Xxxxxxx, XX, 00000. Consultant understands that if he signs this Release and does not revoke the Release within seven calendar days after signing, this Release will become fully effective and enforceable (the “Release Effective Date”). Consultant also understands that no severance payments will be paid to him until the seven-calendar-day revocation period has expired without him having revoked the Release.
Consultant
By:________________________
Date:________________________
844.KEY.CURE | xxx.xxxxxxx.xxx
| Page 4 | |